RE:RE:Roche Tecentriq + Avastin met primary endpoint- liver cancerThe patents on Roche's Avastin expired in the US in July 2019 and in Europe in January 2022.
US-based pharma giant Pfizer announced on 28 June 2019 that it had received approval from the US Food and Drug Administration (FDA) for its bevacizumab biosimilar Zirabev (PF-06439535).
Zirabev has been approved as a biosimilar, not as an interchangeable product.
The approval of Zirabev marked the sixth biosimilar from Pfizer (and its subsidiary Hospira) to be approved by FDA.
Roche's Tecentriq adjusted expiration date is 19 August 2030.